Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLES (Details)

v3.22.2
INTANGIBLES (Details) - USD ($)
$ in Millions
May 13, 2021
Mar. 31, 2021
Mar. 01, 2021
Jul. 29, 2020
Asset purchase agreement | Qbrexza        
Intangibles        
Upfront fees $ 12.5      
Milestone payments payable   $ 144.0    
Percentage of diminution in royalty   50.00%    
Age of patients     9 years  
Purchase price   $ 12.5    
Useful life   7 years    
Asset purchase agreement | Qbrexza | Royalty payment percentage for first two years        
Intangibles        
Period of royalty payments   2 years    
Asset purchase agreement | Qbrexza | Royalty payment percentage for eight years thereafter        
Intangibles        
Term of royalty   8 years    
Asset purchase agreement | Qbrexza | Minimum | Royalty payment percentage for first two years        
Intangibles        
Percent of royalty payments   30.00%    
Asset purchase agreement | Qbrexza | Minimum | Royalty payment percentage for eight years thereafter        
Intangibles        
Percent of royalty payments   12.00%    
Asset purchase agreement | Qbrexza | Maximum | Royalty payment percentage for first two years        
Intangibles        
Percent of royalty payments   40.00%    
Asset purchase agreement | Qbrexza | Maximum | Royalty payment percentage for eight years thereafter        
Intangibles        
Percent of royalty payments   19.00%    
License And Supply agreement With DRL | Accutane        
Intangibles        
Upfront fees       $ 1.0
Milestone payments payable       4.0
Contingent amount payable       17.0
Amount of expense agreed to pay under the agreement       $ 5.0